All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2018-03-23T12:09:35.000Z

Dr. Miguel-Angel Perales | EBMT 2018 | Immune check-point inhibitors in the context of SCT

By Elina Simanovits, Sara Valente
Featured
Miguel-Angel Perales
Mar 23, 2018
Share:

Bookmark this article

44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, Portugal
Miguel-Angel Perales
Memorial Sloan Kettering Cancer Center, New York, US

  • Dr Perales explains that there have been good results with using checkpoint inhibitors in transplant in Hodgkin lymphoma.
  • He describes a recent German group study comparing the use of upfront checkpoint inhibitors with or without chemotherapy.
  • There can be complications with GvHD in allogeneic transplant and Dr Perales describes a study where transplant was safe with no increased risk of GvHD. 

Immune check-point inhibitors in the context of SCT

More about...
Classical Hodgkin lymphomaCyclophosphamideEBMT 2018Hodgkin lymphomaHodgkin lymphoma, not otherwise specifiedNivolumabPembrolizumab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

AACR 2017 | Immune evasion in Classical Hodgkin Lymphoma

On Sunday 2nd April, the “RAOS02 - Immunotherapy of Lymphoid Malignancies” session was introduced by Margaret A. Shipp, MD, who gave a talk on immune evasion in Classical Hodgkin Lymphoma (cHL).

Apr 4, 2017
Add bookmark

AACR 2017 | Immune evasion in Classical Hodgkin Lymphoma

On Sunday 2nd April, the “RAOS02 - Immunotherapy of Lymphoid Malignancies” session was introduced by Margaret A. Shipp, MD, who gave a talk on...

Apr 4, 2017
Add bookmark

ASCO 2016 | Poster Discussion - PD-1 Inhibitors in Hodgkin Lymphoma

This poster discussion at ASCO 2016, focused on abstracts 7535 and 7555, on treatment of Hodgkin Lymphoma with PD-1 inhibitors, was presented by Nancy Bartlett.

Nov 15, 2016
Add bookmark

ASCO 2016 | Poster Discussion - PD-1 Inhibitors in Hodgkin Lymphoma

This poster discussion at ASCO 2016, focused on abstracts 7535 and 7555, on treatment of Hodgkin Lymphoma with PD-1 inhibitors, was...

Nov 15, 2016

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox